News
Featured
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium, a new consortium co-led by investigators from Weill Cornell Medicine; the University of California, San Francisco; Johns Hopkins Medicine; and Vanderbilt University Medical Center. The grant, awarded in March 2024, aids the PreDicTR consortium with aims to accelerate the...
News
24 Oct 2013
Click to access report. This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional...
9 Sep 2013
By: Shashank Gupta ( sgupta33@jhmi.edu ) In a significant finding for millions of TB patients, researchers have recently shown that adjunct chemotherapy with verapamil can accelerate tuberculosis treatment in mouse model. Investigators at Johns Hopkins School of Medicine have found that adding...
5 Sep 2013
You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 at Le Méridien Etoile in Paris, France, on Oct. 29th from 15:00 to 19:00. This meeting is held before the 44th Union World Conference on Lung Health (The Union). During the meeting we will review...
27 Aug 2013
Image Courtesy of Expert Medical Education This interactive workshop is held in conjunction with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The workshop is intended to provide clinicians, researchers, students and representatives from regulatory non-government...
29 Jul 2013
Source: Bloomberg http://www.bloomberg.com/news/2013-07-26/otsuka-s-drug-resistant-tb-treatment-fails-to-win-ema-nod.html Otsuka’s Drug-Resistant TB Treatment Fails to Win EMA Nod Otsuka Holdings Co. (4578) failed to win the backing of a European Medicines Agency panel for the Delamanid medicine...
16 Jul 2013
Source: http://www.bloomberg.com/article/2013-07-17/adCNbBPYeTyM.html Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc’s exclusive worldwide rights to develop and...
9 Jul 2013
Yesterday, the US National Public Radio posted online two insightful pieces on tuberculosis. What It Takes To Cure Drug-Resistant Tuberculosis Treating The ‘Body And Soul’ In A Russian TB Prison Please check it out and pass along.
8 Jul 2013
Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB) . Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a...
30 Jun 2013
Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...
23 Jun 2013
We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort , Lucca (Barga), Italy. The workshop is held in conjunction with the Gordon Conference...
12 Jun 2013
From the Stop TB Parntership News: The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline was granted accelerated approval by the United States Food and Drug...
22 May 2013
Vilchèze C, Hartman T, Weinrick B, and Jacobs W. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction . Nature Communications. 2013 May 21; 4(1881). doi:10.1038/ncomms2898 Abstract: Drugs that kill tuberculosis more quickly could shorten...
14 May 2013
Update: Release of Part 1 of EXPOSED scheduled for the week of May 20. Contact jrosen@aeras.org if you would like to host a screening event or get more information. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will...
25 Apr 2013
Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access , 2) on adaptive clinical trial designs , and 3) on pediatric drug development needs . The full...
15 Apr 2013
MSF Scientific Day 2013 will be streamed live online from the Royal Society of Medicine, London, UK, from 09.00am – 06.00pm (GMT+1) on 10 th May 2013 http://www.msf.org.uk/Scientific_Day.aspx MSF Scientific Day is a unique opportunity to showcase medical and scientific research carried out in MSF...